Florence I. Raynaud

19.2k total citations · 2 hit papers
242 papers, 10.2k citations indexed

About

Florence I. Raynaud is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Florence I. Raynaud has authored 242 papers receiving a total of 10.2k indexed citations (citations by other indexed papers that have themselves been cited), including 144 papers in Molecular Biology, 70 papers in Oncology and 32 papers in Cell Biology. Recurrent topics in Florence I. Raynaud's work include Microtubule and mitosis dynamics (23 papers), Cancer, Hypoxia, and Metabolism (22 papers) and Cancer-related Molecular Pathways (20 papers). Florence I. Raynaud is often cited by papers focused on Microtubule and mitosis dynamics (23 papers), Cancer, Hypoxia, and Metabolism (22 papers) and Cancer-related Molecular Pathways (20 papers). Florence I. Raynaud collaborates with scholars based in United Kingdom, France and United States. Florence I. Raynaud's co-authors include Paul Workman, Ian Judson, Paul A. Clarke, Johann S. de Bono, Lloyd R. Kèlland, Timothy A. Yap, Michelle D. Garrett, Finbarr E. Cotter, David Cunningham and Melanie Valenti and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Florence I. Raynaud

238 papers receiving 10.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

2008 666 citations Gerhardt Attard, Alison Reid et al. Journal of Clinical Oncology profile →
Effect of sleep deprivation on the human metabolome

2014 387 citations Joo Ern Ang, Victoria L. Revell et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Florence I. Raynaud United Kingdom	55	5.5k	2.6k	2.1k	1.2k	1.0k	242	10.2k
John S. Lazo United States	61	7.9k 1.4×	2.9k 1.1×	1.1k 0.5×	1.4k 1.2×	1.5k 1.4×	323	13.5k
Daret K. St. Clair United States	64	6.8k 1.2×	1.6k 0.6×	1.8k 0.9×	1.7k 1.4×	552 0.5×	175	12.9k
Phillip A. Dennis United States	49	7.6k 1.4×	4.6k 1.7×	2.5k 1.2×	2.2k 1.8×	463 0.4×	137	12.4k
Gary L. Firestone United States	57	7.4k 1.3×	1.6k 0.6×	1.0k 0.5×	1.0k 0.8×	1.1k 1.0×	156	11.2k
Robert Roskoski United States	57	9.9k 1.8×	4.1k 1.5×	2.1k 1.0×	1.4k 1.2×	1.6k 1.5×	173	16.3k
Kenneth V. Honn United States	63	5.0k 0.9×	2.9k 1.1×	1.3k 0.6×	3.4k 2.8×	614 0.6×	243	12.8k
Doriano Fabbro Switzerland	74	12.4k 2.3×	3.7k 1.4×	1.5k 0.7×	1.4k 1.1×	1.8k 1.7×	223	20.3k
Li Li China	48	4.7k 0.9×	2.1k 0.8×	1.5k 0.7×	1.4k 1.2×	437 0.4×	420	9.9k
Yong J. Lee United States	57	6.6k 1.2×	1.6k 0.6×	931 0.5×	1.7k 1.4×	482 0.5×	253	10.6k
Craig J. Thomas United States	61	7.0k 1.3×	1.6k 0.6×	764 0.4×	1.9k 1.6×	1.7k 1.7×	250	15.2k

Countries citing papers authored by Florence I. Raynaud

Since Specialization

Citations

This map shows the geographic impact of Florence I. Raynaud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Florence I. Raynaud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Florence I. Raynaud more than expected).

Fields of papers citing papers by Florence I. Raynaud

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Florence I. Raynaud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Florence I. Raynaud. The network helps show where Florence I. Raynaud may publish in the future.

Co-authorship network of co-authors of Florence I. Raynaud

This figure shows the co-authorship network connecting the top 25 collaborators of Florence I. Raynaud. A scholar is included among the top collaborators of Florence I. Raynaud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Florence I. Raynaud. Florence I. Raynaud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kumar, Rajiv, Dionysis Papadatos-Pastos, Joaquı́n Mateo, et al.. (2020). First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors. Clinical Cancer Research. 26(18). 4777–4784. 52 indexed citations

Stewart, Adam, Elizabeth A. Coker, Sebastian Pölsterl, et al.. (2019). Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS -Mutant Cancers. Molecular Cancer Therapeutics. 18(8). 1396–1404. 14 indexed citations

Andrejeva, Gabriela, Sharon Gowan, Gigin Lin, et al.. (2019). De novo phosphatidylcholine synthesis is required for autophagosome membrane formation and maintenance during autophagy. Autophagy. 16(6). 1044–1060. 76 indexed citations

Ang, Joo Ern, Ákos Pál, Yasmin J. Asad, et al.. (2017). Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma. Molecular Cancer Therapeutics. 16(10). 2315–2323. 8 indexed citations

Yogev, Orli, Karen Barker, Gilberto S. Almeida, et al.. (2016). p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance. Cancer Research. 76(10). 3025–3035. 32 indexed citations

Ang, Joo Ern, Yasmin J. Asad, Alan T. Henley, et al.. (2016). Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation. Molecular Cancer Therapeutics. 15(6). 1412–1424. 16 indexed citations

Renshaw, Jane, Kathryn R. Taylor, Ryan T. Bishop, et al.. (2013). Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo. Clinical Cancer Research. 19(21). 5940–5951. 110 indexed citations

Banerji, Udai, Leni van Doorn, Dionysis Papadatos-Pastos, et al.. (2012). A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors. Clinical Cancer Research. 18(9). 2687–2694. 64 indexed citations

Walton, Mike I., Paul D. Eve, Angela Hayes, et al.. (2012). CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs. Clinical Cancer Research. 18(20). 5650–5661. 69 indexed citations

10.

Faisal, Amir, Vassilios Bavetsias, Chongbo Sun, et al.. (2011). The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN -Amplified Neuroblastoma In Vivo. Molecular Cancer Therapeutics. 10(11). 2115–2123. 67 indexed citations

11.

Bielen, Aleksandra, Lara Perryman, Gary Box, et al.. (2011). Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β. Molecular Cancer Therapeutics. 10(8). 1407–1418. 41 indexed citations

12.

Pacey, Simon, Richard H. Wilson, Mike Walton, et al.. (2011). A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors. Clinical Cancer Research. 17(6). 1561–1570. 154 indexed citations

13.

Yap, Timothy A., Mike I. Walton, Melanie Valenti, et al.. (2010). Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930. Molecular Cancer Therapeutics. 10(2). 360–371. 59 indexed citations

14.

Al-Saffar, Nada M.S., L. Elizabeth Jackson, Florence I. Raynaud, et al.. (2010). The Phosphoinositide 3-Kinase Inhibitor PI-103 Downregulates Choline Kinase α Leading to Phosphocholine and Total Choline Decrease Detected by Magnetic Resonance Spectroscopy. Cancer Research. 70(13). 5507–5517. 54 indexed citations

15.

Walton, Michael I., Paul D. Eve, Angela Hayes, et al.. (2010). The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106. Molecular Cancer Therapeutics. 9(1). 89–100. 63 indexed citations

16.

Ewan, Kenneth, Bożena Pająk, Mark Stubbs, et al.. (2010). A Useful Approach to Identify Novel Small-Molecule Inhibitors of Wnt-Dependent Transcription. Cancer Research. 70(14). 5963–5973. 86 indexed citations

17.

Workman, Paul, Paul A. Clarke, Florence I. Raynaud, & Rob L. M. van Montfort. (2010). Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic. Cancer Research. 70(6). 2146–2157. 211 indexed citations

18.

Gril, Brunilde, Sylvie Dufour, Réda Hadj-Slimane, et al.. (2008). Capns1, a new binding partner of RasGAP-SH3 domain in K-RasV12 oncogenic cells: Modulation of cell survival and migration. Cellular Signalling. 20(11). 2119–2126. 15 indexed citations

19.

Attard, Gerhardt, Alison Reid, Timothy A. Yap, et al.. (2008). Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven. Journal of Clinical Oncology. 26(28). 4563–4571. 666 indexed citations breakdown →

20.

Banerji, Udai, Michael I. Walton, Florence I. Raynaud, et al.. (2005). Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models. Clinical Cancer Research. 11(19). 7023–7032. 126 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact